Novartis reports 52‑week Phase III data showing sustained efficacy of Rhapsido in chronic inducible urticaria

Novartis presented 52‑week results from the Phase III RemIND trial of Rhapsido (remibrutinib) in patients with chronic inducible urticaria (CIndU). The study showed that patients receiving the drug maintained symptom improvement across the three main subtypes—symptomatic dermographism, cold urticaria and cholinergic urticaria—through week 52, and those who switched from placebo at week 24 achieved comparable response rates. The safety record remained stable over the year‑long period. Novartis said it will file further regulatory submissions to seek label extensions for the additional CIndU subtypes.

The additional submissions could broaden Rhapsido’s approved indications, potentially increasing its market size. Analysts at GlobalData estimate the drug could generate about $5 billion in sales by 2032, which would add a significant revenue stream for Novartis.

  • 1The RemIND trial enrolled 362 CIndU patients and randomized them to Rhapsido 25 mg twice daily or placebo.
  • 2At week 52, complete or partial response rates for patients on Rhapsido were 46.8% (SD), 83.3% (ColdU) and 58.2% (CholU).
  • 3Patients who switched from placebo to Rhapsido at week 24 reached response rates of 47.7% (SD), 88.9% (ColdU) and 69.8% (CholU) by week 52.
  • 4The safety profile through week 52 was consistent with earlier studies and no new safety signals were observed.
  • 5Novartis plans to submit additional regulatory filings to pursue approvals for the cold and cholinergic urticaria subtypes.
  • 6GlobalData projects Rhapsido sales could approach $5 billion in 2032.

Sources